Clinical Performance of Low-Profile Bioprostheses: Results at 10 Years
| Autor: | Carlo Bassano, Fiorella Giacopino, Giorgio Rabitti, Giovanni Battista Bertoletti, Michele Danilo Pierri, Luigi C. D'alessandro, Fabrizio Nesi, Vittorio Creazzo |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male Reoperation Pulmonary and Respiratory Medicine Aortic valve medicine.medical_specialty Prosthesis-Related Infections Time Factors Adolescent Periprosthetic 030204 cardiovascular system & hematology Settore ICAR/01 - Idraulica 03 medical and health sciences 0302 clinical medicine Actuarial Analysis Thromboembolism Mitral valve Statistical significance medicine Humans Child Retrospective Studies Bioprosthesis Endocarditis business.industry Incidence (epidemiology) Graft Survival Clinical performance Retrospective cohort study Middle Aged Surgery Survival Rate medicine.anatomical_structure Standard error 030228 respiratory system Aortic Valve Heart Valve Prosthesis Mitral Valve Female Tricuspid Valve Cardiology and Cardiovascular Medicine business Follow-Up Studies |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 0886-0440 |
| DOI: | 10.1111/jocs.1991.6.4s.568 |
| Popis: | The purpose of this retrospective study is to evaluate the long-term performance of the Liotta minimally intrusive bioprosthesis (MIB) and to identify its most important risk factors. From January 1980 to March 1982, 73 patients (30 males and 43 females; mean age 45.5 years +/- 11.7 standard deviation; range 11 to 64) underwent operation for heart valve replacement with an MIB. Fifty-two mitral valve replacements (MVR), 16 aortic valve replacements (AVR), 4 mitral and aortic valve replacements (MAVR), and 1 mitral and tricuspid valve replacement (MTVR) have been performed (78 MIBs implanted). Global operative mortality has been 8.2% (6/73): 9.6% (5/52) for MVR and 6.2% (1/16) for AVR. The 10-year follow-up reaches 519 patient-years and 581 valve-years, and is 96.5% and 93.9% complete, respectively. Actuarial freedom from any patient- or valve-related event has been calculated at one time with its hazard function and its incidence normalized per 100 patient- and/or valve-years; statistical significance of difference between curves has been assessed. In this report, overall actuarial survival at 10 years is 79.4% +/- 5.3% SEM (standard error of the mean), including operative deaths (incidence = 2.6% per patient-year). Two patients experienced periprosthetic leakage (PL) at 4 and 9 years, respectively (incidence = 0.4% per valve-year). One patient underwent reoperation because of otherwise untreatable prosthetic valve endocarditis (PVE) at 5 years (0.2% per valve-year).(ABSTRACT TRUNCATED AT 250 WORDS) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|